Ewing Alexander C, Datwani Hema M, Flowers Lisa M, Ellington Sascha R, Jamieson Denise J, Kourtis Athena P
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Am J Obstet Gynecol. 2016 Oct;215(4):499.e1-8. doi: 10.1016/j.ajog.2016.05.048. Epub 2016 Jun 2.
With the development and widespread use of combination antiretroviral therapy, HIV-infected women live longer, healthier lives. Previous research has shown that, since the adoption of combination antiretroviral therapy in the United States, rates of morbidity and adverse obstetric outcomes remained higher for HIV-infected pregnant women compared with HIV-uninfected pregnant women. Monitoring trends in the outcomes these women experience is essential, as recommendations for this special population continue to evolve with the progress of HIV treatment and prevention options.
We conducted an analysis comparing rates of hospitalizations and associated outcomes among HIV-infected and HIV-uninfected pregnant women in the United States from 2004 through 2011.
We used cross-sectional hospital discharge data for girls and women age 15-49 from the 2004, 2007, and 2011 Nationwide Inpatient Sample, a nationally representative sample of US hospital discharges. Demographic characteristics, morbidity outcomes, and time trends were compared using χ(2) tests and multivariate logistic regression. Analyses were weighted to produce national estimates.
In 2011, there were 4751 estimated pregnancy hospitalizations and 3855 delivery hospitalizations for HIV-infected pregnant women; neither increased since 2004. Compared with those of HIV-uninfected women, pregnancy hospitalizations of HIV-infected women were more likely to be longer, be in the South and Northeast, be covered by public insurance, and incur higher charges (all P < .005). Hospitalizations among pregnant women with HIV infection had higher rates for many adverse outcomes. Compared to 2004, hospitalizations of HIV-infected pregnant women in 2011 had higher odds of gestational diabetes (adjusted odds ratio, 1.81; 95% confidence interval, 1.16-2.84), preeclampsia/hypertensive disorders of pregnancy (adjusted odds ratio, 1.58; 95% confidence interval, 1.12-2.24), viral/mycotic/parasitic infections (adjusted odds ratio, 1.90; 95% confidence interval, 1.69-2.14), and bacterial infections (adjusted odds ratio, 2.54; 95% confidence interval, 1.53-4.20). Bacterial infections did not increase among hospitalizations of HIV-uninfected pregnant women.
The numbers of hospitalizations during pregnancy and delivery have not increased for HIV-infected women since 2004, a departure from previously estimated trends. Pregnancy hospitalizations of HIV-infected women remain more medically complex than those of HIV-uninfected women. An increasing trend in infections among the delivery hospitalizations of HIV-infected pregnant women warrant further attention.
随着联合抗逆转录病毒疗法的发展和广泛应用,感染艾滋病毒的女性寿命更长,生活更健康。先前的研究表明,自美国采用联合抗逆转录病毒疗法以来,与未感染艾滋病毒的孕妇相比,感染艾滋病毒的孕妇的发病率和不良产科结局发生率仍然更高。随着艾滋病毒治疗和预防方案的进展,针对这一特殊人群的建议不断演变,因此监测这些女性所经历结局的趋势至关重要。
我们进行了一项分析,比较了2004年至2011年美国感染艾滋病毒和未感染艾滋病毒的孕妇的住院率及相关结局。
我们使用了2004年、2007年和2011年全国住院患者样本中15至49岁女性的横断面医院出院数据,该样本是美国医院出院情况的全国代表性样本。使用χ²检验和多因素逻辑回归比较人口统计学特征、发病结局和时间趋势。分析进行了加权以得出全国估计数。
2011年,估计有4751例感染艾滋病毒的孕妇因妊娠住院,3855例因分娩住院;自2004年以来均未增加。与未感染艾滋病毒的女性相比,感染艾滋病毒的女性妊娠住院时间更可能更长,住院地区多在南部和东北部,由公共保险支付费用,且费用更高(所有P <.005)。感染艾滋病毒的孕妇住院时许多不良结局的发生率更高。与2004年相比,2011年感染艾滋病毒的孕妇住院患妊娠期糖尿病的几率更高(调整优势比,1.81;95%置信区间,1.16 - 2.84)、子痫前期/妊娠高血压疾病(调整优势比,1.58;95%置信区间,1.12 - 2.24)、病毒/真菌/寄生虫感染(调整优势比,1.90;95%置信区间,1.69 - 2.14)以及细菌感染(调整优势比,2.54;95%置信区间,1.53 - 4.20)。未感染艾滋病毒的孕妇住院期间细菌感染情况未增加。
自2004年以来,感染艾滋病毒的女性妊娠和分娩期间的住院人数未增加,这与先前估计的趋势不同。感染艾滋病毒的女性妊娠住院在医学上仍比未感染艾滋病毒的女性更为复杂。感染艾滋病毒的孕妇分娩住院期间感染呈上升趋势值得进一步关注。